The Food & Drug Administration (FDA) announced its approval of an injectable form of buprenorphine (brand name: Sublocade), a medication used to treat opiate addiction. Sublocade releases a steady ...
PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Earnings call Indivior delivered a strong Q1 2026, with total net revenue up 19% year-over-year to $317 million and SUBLOCADE net revenue up 32% to $232 million. Adjusted EBITDA more than doubled, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results